MedTrace Logo

SPRiNG: SCIO-469 Patients With Rheumatoid Arthritis Not Receiving Methotrexate

NCT00089921 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 302

Last updated 2010-10-18

No results posted yet for this study

Summary

The primary objective of this study is to determine the efficacy of oral SCIO-469 in patients with rheumatoid arthritis who are not receiving liver damaging (hepatotoxic) disease-modifying anti-rheumatic drugs (DMARDs).

Conditions

  • Arthritis, Rheumatoid

Interventions

DRUG

SCIO-469

60 mg capsule three times daily for 12 weeks

DRUG

SCIO-469

30 mg capsule three times daily for 12 weeks

DRUG

Placebo

2 capsules three times daily and one tablet daily

DRUG

SCIO-469

100 mg tablet once daily for 12 weeks

Sponsors & Collaborators

  • Scios, Inc.

    lead INDUSTRY

Principal Investigators

  • Scios, Inc. Clinical Trial · Scios, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Completion
2005-10-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00089921 on ClinicalTrials.gov